The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.

Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared ...

mRNA, widely known from the COVID-19 vaccine, is not actually a “therapeutic agent,” but a technology that delivers the blueprint for functional proteins into the body so that induces therapeutic ...

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 ...

Postdoctoral fellow and co-first author Dongyoon Kim demonstrates some of the equipment used to craft the new ionizable lipids. [Bella Ciervo, Penn Engineering] The explosion of mRNA vaccines brought ...

A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according ...

The skin cancer vaccine is based on mRNA technology that helped end the coronavirus pandemic.

Moderna (MRNA) faces major commercial setbacks as mRNA vaccines underperform against traditional competitors in post-pandemic markets. RSV and flu mRNA vaccines struggle with lower durability, higher ...

A new mRNA flu vaccine offering stronger protection against influenza could soon become available in Canada as Health Canada ...

For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 ...